Introduction: The relationship between the angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism and psoriasis has previously been studied mainly in Caucasians and only once in Asians. The aim of this study is to evaluate the association between the ACE I/D polymorphism and the risk of psoriasis in a Chinese population.
Introduction
Psoriasis is a common, chronic inflammatory skin disease characterized by keratinocyte hyperproliferation and increased blood flow induced by the stimulation of tissueresident immune cells by markedly altered cutaneous cytokine profiles. 1 Psoriasis affects approximately 2% of the general population. 2 It is a complex, multifactorial disease. Genetic as well as environmental factors contribute to the susceptibility and severity of psoriasis. Although the multifactorial etiology of psoriasis is well established, family and twin studies indicate a strong genetic component. 3 During the past five years, genome-wide association studies (GWAS), primarily based on single nucleotide polymorphism markers, have identified many loci as potential psoriasis susceptibility regions. 4, 5 Angiotensin-converting enzyme (ACE) is an important circulating enzyme in the renin-angiotensin-aldosterone system (RAAS). 6 ACE is expressed in a wide range of tissues including skin, vascular endothelium and immune cells. [7] [8] [9] [10] [11] Plasma and tissue concentration of ACE are determined by the ACE gene (chromosome 17q23). 12 The ACE gene has functional insertion/deletion (I/D) polymorphism of a 287 bp Alu sequence within intron 16. 13 ACE DD carriers have higher local levels of ACE than those with the ID and II genotypes. 13, 14 Almost half of patients with psoriasis have been found to have elevated serum ACE activity. 15 The relationship between the ACE I/D polymorphism and psoriasis has previously been studied mainly in Caucasians and only once in Asians. [16] [17] [18] [19] [20] The aim of this study is to evaluate the association between ACE I/D polymorphism and the risk of psoriasis in a Chinese population.
Materials and methods

Study population
This is a hospital-based case-control study. The study population consisted of 668 psoriasis patients and 668 matched control subjects. Patients with psoriasis were diagnosed by clinical and/or histopathological findings. Patients were considered to have "early onset" psoriasis if disease onset was at any age younger than 40 years and "late onset" psoriasis if age at onset was after their 40th birthday. Patients were considered to have "familial" psoriasis if they had one or more first-or second-degree relatives affected by the condition, or to have "sporadic" psoriasis if this was not the case. In addition, patients with a positive family history and early-onset disease were classified as having "type I psoriasis," and patients with a negative family history and lateonset disease were classified as having "type II psoriasis." At the time of enrollment the Psoriasis Area and Severity Index (PASI) scores was calculated. Control subjects were recruited during routine health examinations and met the following criteria: (1) no clinical evidence of psoriasis; (2) similar age and sex distribution; (3) no family history of psoriasis; (4) no coexisting disease (hypertension, diabetes, sarcoidosis, etc.); and (5) the same population as the cases. The study protocol was approved by the hospital ethics committee, and all participants gave written informed consent according to the Declaration of Helsinki.
DNA extraction and genotyping
DNA extraction from paraffin section was carried out by Qiamp kit (Qiagen, Germany) according to the manufacturer's instructions. The ACE I/D gene polymorphism was analyzed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Based on the GenBank reference sequence, the PCR primers were as follows: forward-5'-CTGGAGACCACTCCCATCCTTTCT -3' and reverse-5'-GATGTGGCCATCACATTCGTCAGAT -3'. DNA was denaturated at 94°C for five minutes, followed by 30 cycles of denaturation at 94°C for one minute, annealing at 67°C for one minute, and extension at 72°C for two minutes, with a final extension step of five minutes at 72°C. PCR products (490-bp insertion and 190-bp deletion) were separated by 2% agarose gel electrophoresis, stained with ethidium bromide, and viewed with ultraviolet (UV) light.
Statistical analysis
SPSS ® software version 16.0 (SPSS Inc, IL, USA) was used for statistical analysis. Differences between continuous variables were assessed by Student's t test, while those between categorical variables were evaluated using Pearson x 2 test. The existence of differences in allelic and genotypic frequencies between different groups was assessed by means of Pearson x 2 test. Odds ratios (OR) and 95% confidence intervals (CI) were determined by logistic regression analysis. P < 0.05 was considered statistically significant.
Results
The characteristics of patients with psoriasis and controls are shown in Table 1 . As to clinical characteristics, there was no statistical significant difference in age (P = 0.27) or gender (P = 0.53) between the patients with psoriasis and control groups, as shown in Table 1 . Their family history was as follows: positive (familial), 262 (39.2%); negative (sporadic), 406 (60.8%). The onset of the disease was as follows: early-onset, 478 (71.6%); late-onset, 190 (28.4%). The type of psoriasis was as follows: type I, 235 (35.2%); type II, 182 (27.2%). The severity of psoriasis was as follows: nonsevere, 598 (89.5%); severe, 70 (10.5%). The frequency of the ACE II genotype (OR = 1.32, 95% CI = 1.06, 1.63; P = 0.01) and I allele (OR = 1.25, 95% CI = 1.06, 1.48; P = 0.01) in patients with psoriasis was significantly higher than that in the control group (Table 2) . And the D allele frequency in patients with psoriasis was significantly lower (OR = 0.80, 95% CI = 0.68, 0.95; P = 0.01) than that in the control group (Table 2) . When stratified by family history, the frequency of the DD genotype was significantly lower in patients with a positive family history of psoriasis (familial psoriasis) than in those with negative (sporadic psoriasis) (OR = 0.47, 95% CI = 0.23, 0.97; P = 0.04) ( Table 3) . When stratified by onset of the disease, type of psoriasis and severity of psoriasis, no statistically significant result was observed ( Table 3 ).
Discussion
The relationship between the ACE I/D polymorphism and psoriasis has previously been studied mainly in Caucasians and only once in Asians. [16] [17] [18] [19] [20] Ozkur et al. first investigated the association of ACE I/D polymorphism and psoriasis. 20 They found that that the presence of the ACE I allele might confer susceptibility to development of psoriasis in individuals from psoriatic families in Turkey. 20 Chang et al. also found that the presence of the ACE I allele might confer susceptibility to development of psoriasis among ethnically Chinese Taiwanese individuals. 19 Weger et al. found that homozygosity for the ACE I allele might affect susceptibility to early-onset psoriasis in Austria. 17 A meta-analysis was conducted on the association between the ACE I/D polymorphisms and psoriasis. 21 No difference was found between the distribution of the ACE genotype in psoriatic arthritis patients and the general population in Kuwait. 18 Coto-Segura et al. found that the ACE polymorphism was not likely to be associated with either psoriasis or psoriatic arthritis in Spain. 16 In the last decade, many studies have been conducted to investigate the genetic factors of psoriasis. A meta-analysis of seven studies with 966 patients and 1086 controls suggested that ApoE polymorphisms were associated with the risk of psoriasis, especially epsilon2 and epsilon3 alleles. 22 A meta-analysis of 13 studies demonstrated a significant association between IL23R gene polymorphisms and psoriasis. 23 A case-control study suggested that GJB2 gene polymorphism rs3751385:C>T was associated with psoriasis susceptibility of a Chinese Han population. 24 A metaanalysis of nine studies suggested that the vitamin D receptor (VDR) ApaI polymorphism conferred susceptibility to psoriasis in a Turkish population. 25 A meta-analysis of eight studies involving 1018 psoriasis patients and 1186 controls shows that the IL-10-1082 G/A polymorphism confers susceptibility to psoriasis in Asians, and suggests that the IL-10 promoter -1082 polymorphism has an ethnicity-specific effect. 26 The molecular mechanism of the association between ACE I/D polymorphism and the risk of psoriasis is still relatively unclear. ACE and its related substrates or products are known to have wide-ranging effects on cutaneous immune and inflammatory responses. 27, 28 Almost half of patients with psoriasis have been found to have elevated serum ACE activity. 15 Furthermore, treatments with ACE inhibitors have been reported to induce or aggravate psoriasis manifestations. 29, 30 The ACE I/D polymorphism strongly affects ACE activities, with homozygotes for the ACE I allele showing lower activities than those carrying the ACE DD genotype. 13, 14 Taken together, these results suggest that the ACE I/D polymorphism may be a genetic factor contributing to the heritability of psoriasis susceptibility.
The strength of this study was a relatively large sample size. Some limitations of this study should be taken into account when interpreting the findings. First of all, these results should be interpreted with caution because the patient sample was limited to a Chinese population, which reduces the possibility of confounding because of ethnicity, but does not permit extrapolation of the results to other ethnic groups. Second, although our and other epidemiologic studies suggested statistically significant interactions between ACE I/D polymorphism and psoriasis risk, more biological background data are needed to explain our results. Third, another limitation of this work is that the current finding might involve gene-to-environment interactions, which were not explored in the present study.
In conclusion, our study suggested that ACE II genotype and I allele might confer susceptibility to psoriasis in a Chinese population. More genetic risk variants and other 
